エムバイオテック

JAPANESE | CHINESE | ENGLISH



Home Page | News | Mycoplasma Infection Diseases | Healthcare Organizations | Link | Company


           
       Bussiness    
       Precision Preventative Medicine    
 
  • Company overview
  • Message From President
  • Basic Technology
Busines
  • Products
  • Stock Information
  M Bio Technology Inc. is the innovative biotechnology company.

M Bio Technology Inc. is focusing the diagnosis, therapeutic and prevention of Mycoplasma Infectious Diseases(MID)

Mycoplasma Infectious Diseases (MID) cause systemic vasculitis/neuritis and to be the cause of chronic or incurable disease.

Mycoplasma infection cause not only pneumonia but vasculitis based asthma, arthritis, nephritis, meningitis, encephalitis, arteritis, dermatitis.

Further, Mycoplasma Infectious Disease (MID)presents variegated condition, such as autoimmune diseases, rheumatic disease and a nervous system disorders, innflammatory diseases.

Clinicallly, it become oftenly important to determine the cause of interstitial pneumonia and/or Stevens-Johnson syndrome, whether severe side effect of drug or mycoplasma. including Stevens-Johnson syndrome (SJS), Kawasaki disease, or Multiple Sclerosis (MS).

The mycoplasma vaccine and diagnostics using the synthesized glycolipid antigen are world's first platform technology.

The concept of vaccine for MID is First in Class, simplest vaccine, whose component are chemically-synthesized glycolipid-antigens.

The core technology is structural anlysis and chemical synthesis of mycoplasma lipid-antigens. The microorganism lipid antigen analysis technology is introduced into clinical diagnosis-treatment, and it challenges overcoming the disease to which the lipid antigen is related.

It becomes possible to discover MID at an early stage, and to treat a cause of a disease curatively with this medical treatment.

We are creating global network for for the precision medicine, and seeking for partners to develop companion diagnostic, vaccine, the partner of maycoplasma vaccine in the pharmaceutical companies and biotech industries world wide.

It is assumed to be a mission to put study results of the mycoplasma lipid antigen to practical use, and to contribute to the establishment of diagnosis-prevention-treatment method of the mycoplasma infectious disease.
   
           
 
     
           
  




Home Page | News | Mycoplasma Infection Diseases | Healthcare Organizations | Link | Company

Copyright© 2013 M Bio Technology Inc. All Rights Reserved.